Do you want to read an article? Please log in or register.
Impact at school age of early chronic methicillin-sensitive Staphylococcus aureus infection in children with cystic fibrosis
Pulmonary FibrosisBronchi
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Wolter DJ, Onchiri FM, Emerson J, Precit MR, Lee M, McNamara S, Nay L, Blackledge M, Uluer A, Orenstein DM, Mann M, Hoover W, Gibson RL, Burns JL, Hoffman LR, SCVSA study group.
doi: 10.1016/S2213-2600(19)30365-0.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Pulmonary Fibrosis
Lung Clearance Index to Track Acute Respiratory Events in School-age Children with Cystic Fibrosis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, Sanders DB, Davis SD, Ratjen F
doi: 10.1164/rccm.202006-2433OC.Visit the original publication at ncbi.nlm.nih.gov
Pulmonary Fibrosis
Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency
J Cyst Fibros.
Thursfield RM, Naderi K, Leaver N, Rosenthal M, Alton EWFW, Bush A, Davies JC
doi: 10.1016/j.jcf.2018.02.011.
RECOMMENDED
Pulmonary Fibrosis
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Am J Respir Crit Care Med.
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, Graff GR, Kerby GS, Orenstein D, Buckingham R, Ramsey BW; OPTIMIZE Study Group
doi: 10.1164/rccm.
RECOMMENDED
Pulmonary Fibrosis
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
Lancet Respir Med.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS
doi: 10.1016/S2213-2600(18)30460-0.
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Lancet Respir Med.
Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group
doi: 10.1016/S2213-
Asthma
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections
Clin Infect Dis.
Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P, Antimicrobial Resistance International Working Group in Cystic Fibrosis.
doi: 10.1093/cid/ciz364.
RECOMMENDED
Pulmonary Fibrosis
Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
doi: 10.1002/ppul.24766.